Tandem Diabetes Care, Inc.
TNDMHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Tandem Diabetes Care, Inc. (TNDM) is listed under Medical Devices. The $1.17B market capitalization puts TNDM squarely in small-cap range for its industry. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.
Market Cap
$1.17B
Beta
1.58
P/E (TTM)
—
P/E (Fwd)
150.13
EPS (TTM)
$-1.44
EPS (Fwd)
$0.11
ROE
-65.7%
ROA
-3.7%
Cash
$570.3M
Total Debt
$734.7M
Free CF
-$20.3M
52W Change
15.6%
Annual Financials
Cash vs Debt
On the balance sheet, TNDM has $570.3M in cash with $734.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$20.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -65.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $801.2M (2022) to $1.01B (2025), reflecting a 27% increase over the period.
Tandem Diabetes Care, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TNDM.